OBJECTIVES: An elevated number of absence days and disability affect both employers and employees as a result of pneumococcal diseases. This study aims to estimate the impact of a 13-Valent Pneumococcal vaccination program from employer´s perspective in a medium size Mexican-Corporate setting. METHODS: A decision tree was built in order to estimate yearly productivity losses and absence days avoided, as well as pneumococcal disease treatment costs. Local incidence of pneumococcal diseases as well as mortality rates were extracted from published and Mexican Government databases. Treatment costs were retrieved from the most representative Mexican public healthcare provider. The cost of the vaccine was provided by the manufacturer. A base scenario of a 1,000 employee company  with a homogeneous distribution of ages (18<x<65) was assumed to show the potential benefits of the program in patients between 50 and 65 years old (average monthly wage: US$779). Productivity losses are expressed in 2013 US$ (5% discount rate/year). A bivariate sensitivity analysis of both, vaccine cost (+10%) and effectiveness (-10%) was performed. RESULTS: Assuming 50% employee enrollment into the program, and vaccination cost split 50/50 between employer and employee, a single employer investment of US$50 per program participant could potentially generate savings of US$33 for each over a ten year horizon. We estimate 395 absence days can be avoided, representing avoided productivity losses as high as US$8,315 across all participants in ten years. The program becomes cost-saving at year 7, however absences are avoided from the first year. The total treatment plus productivity losses of an invasive infection, in- and outpatient pneumonia are respectively 54, 34 and 47 times higher than the vaccination outlay. Outcomes were robust to a 10% variation in both vaccination cost and effectiveness.  CONCLUSIONS: A 13-Valent Pneumococcal vaccination program could bring potential savings for employers from the seventh year of implementation.